| Beth Junker has over 30 years of experience in the bioprocessing of antibodies; therapeutic proteins; recombinant, DNA, mRNA, conjugate and viral vaccines; gene therapy, and secondary metabolites. She received her B.S.E from Princeton University in Chemical Engineering and her Ph.D. at the Massachusetts Institute of Technology in Biochemical Engineering. After obtaining her PhD she joined Merck & Co. where she made significant technical contributions in process development, clinical pilot plant operations and regulatory filings for commercial products (KEYTRUDA, ZINPLAVA, LUSDANA, ILUMYA/ILUMETRI, VAQTA, CANCIDAS) as well as numerous pipeline product candidates. In 2016, she became an independent consultant and now actively consults for a diverse set of clients. |